Clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular diseases-an updated systematic review

Nagendra Boopathy Senguttuvan1, Vinodhini Subramanian2, Vettriselvi Venkatesan3

  • 1Department of Cardiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, 600116, India. drsnboopathy@gmail.com.

Insights

Clonal hematopoiesis of indeterminate potential (CHIP) mutations are linked to cardiovascular diseases (CVDs). Common CHIP genes like DNMT3A and TET2 increase CVD risk, offering new insights into residual risk management.

Area of Science:

  • Cardiovascular Science
  • Genetics
  • Hematology

Background:

  • Cardiovascular diseases (CVDs) are a leading cause of mortality, with residual risk persisting even with optimal therapy.
  • Clonal hematopoiesis of indeterminate potential (CHIP) involves somatic mutations in blood cells, now linked to increased risk of coronary artery disease and myocardial infarction.
  • Inflammation is a key mediator connecting CHIP mutations and CVDs through cytokine and chemokine pathways.

Purpose of the Study:

  • To systematically review the association between CHIP mutations and CVD.
  • To identify specific CHIP mutations that elevate CVD risk.

Main Methods:

  • Extensive literature search in PubMed and Google Scholar, narrowing down 302 articles to 10 based on pre-specified criteria.
  • CHIP mutation identification using whole-exome sequencing, whole-genome analysis, and single-cell RNA-sequencing.
  • Bioinformatics analysis of commonly mutated CHIP genes using g:Profiler and GeneMANIA for function and interaction insights.

Main Results:

  • A significant association between CHIP mutations and CVD was found in the reviewed literature.
  • DNMT3A, TET2, ASXL1, TP53, JAK2, and SF3B were identified as the most frequently implicated CHIP mutations in CVD patients.
  • Bioinformatics analysis revealed significant interactions for molecular functions, biological processes, and pathways involving these CHIP genes.

Conclusions:

  • A significant association exists between CHIP mutations and CVD, with specific genes like DNMT3A and TET2 being commonly implicated.
  • Understanding the CHIP-CVD link enhances comprehension of residual cardiovascular risk.
  • This knowledge opens new avenues for investigation and therapeutic strategies in managing CVD patients.
Abstract

Related Concept Videos

Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...